Equities Analysts Issue Forecasts for Johnson & Johnson’s FY2018 Earnings (JNJ)
Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Jefferies Group upped their FY2018 earnings per share (EPS) estimates for Johnson & Johnson in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $8.31 for the year, up from their previous forecast of $8.17. Jefferies Group has a “Buy” rating and a $160.00 price target on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2022 earnings at $11.58 EPS.
A number of other analysts have also commented on the company. Citigroup started coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. UBS Group reiterated a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a report on Saturday, September 30th. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 4th. Finally, Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, October 6th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $145.94.
Johnson & Johnson (NYSE JNJ) traded up $0.44 during mid-day trading on Wednesday, hitting $147.36. The stock had a trading volume of 8,705,833 shares, compared to its average volume of 6,040,000. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $395,890.00, a price-to-earnings ratio of 25.58, a PEG ratio of 2.75 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the company earned $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.
A number of large investors have recently added to or reduced their stakes in the business. Stillwater Capital Advisors LLC grew its position in shares of Johnson & Johnson by 1.4% in the second quarter. Stillwater Capital Advisors LLC now owns 89,136 shares of the company’s stock valued at $11,792,000 after purchasing an additional 1,269 shares in the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC grew its position in shares of Johnson & Johnson by 3.6% in the second quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 18,987 shares of the company’s stock valued at $2,511,000 after purchasing an additional 652 shares in the last quarter. Beacon Financial Group grew its position in shares of Johnson & Johnson by 2.1% in the second quarter. Beacon Financial Group now owns 87,012 shares of the company’s stock valued at $11,541,000 after purchasing an additional 1,814 shares in the last quarter. First Command Bank grew its position in shares of Johnson & Johnson by 4.4% in the second quarter. First Command Bank now owns 11,163 shares of the company’s stock valued at $1,476,000 after purchasing an additional 472 shares in the last quarter. Finally, Stock Yards Bank & Trust Co. grew its position in shares of Johnson & Johnson by 5.7% in the second quarter. Stock Yards Bank & Trust Co. now owns 135,744 shares of the company’s stock valued at $17,957,000 after purchasing an additional 7,347 shares in the last quarter. 65.71% of the stock is owned by institutional investors and hedge funds.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.